Immutep(NASDAQ) IMMP

Market Cap$56.99M

Since IPO (2012)-99%

5 Year-89%

1 Year-79%

1 Month-1%

$0.38

-1.76%

-0.01Today

Immutep last closing stock price
Metric	Price	Date
Last close	USD 0.39	2026-07-28

Immutep stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-3.16%	USD 0.40	2026-07-21
1 month	-0.97%	USD 0.39	2026-06-26
3 month	-19.03%	USD 0.48	2026-04-29
Year to date	-86.48%	USD 2.86	2025-12-31
1 year	-78.52%	USD 1.80	2025-07-28
3 year	-82.1%	USD 2.16	2023-07-28
5 year	-88.73%	USD 3.43	2021-07-29
Since inception	-99.04%	USD 40.13	2012-04-17

Immutep Financials at a Glance

Market Cap

$56.99M

Revenue (TTM)

A$12.80M

Net Income (TTM)

-A$127.78M

EPS (TTM)

-$0.37

P/E Ratio

-1.05

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$0.38

Volume

187,632

Open

$0.39

Price

$0.38

Volume

187,632

Open

$0.39

Previous Close

$0.38

Daily Range

$0.37 - $0.39

52-Week Range

$0.29 - $3.53

Estimated Earnings Date

Sep 2, 2026

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$0.38

Volume

187,632

Open

$0.39

Previous Close

$0.38

Daily Range

$0.37 - $0.39

52-Week Range

$0.29 - $3.53

Estimated Earnings Date

Sep 2, 2026

IMMP News

Why Immutep Limited Stock Popped Today

Prosper Junior BakinyApr 8, 2021

IMMP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immutep

Immutep Limited is a biotechnology company focused on developing innovative immunotherapeutic solutions targeting cancer and autoimmune diseases. The company stands out for its pioneering work with the LAG-3 immune checkpoint, which plays a crucial role in regulating the immune response. With its advanced pipeline and key collaborations, Immutep is positioned to address major unmet medical needs.

Products and Services

Eftilagimod Alpha – An immunotherapy in advanced clinical trials targeting cancer.

IMP761 – A preclinical LAG-3 agonist aiming to treat autoimmune diseases.

IMP701 – LAG-3 antibodies developed through partnerships to enhance cancer treatment.

IMP731 – LAG-3 antibodies targeting autoimmune diseases under collaboration.

What Makes Immutep Limited Special

Immutep distinguishes itself with its focus on LAG-3 related immunotherapies, positioning it as a leader in next-generation immune checkpoint development. This strategic focus helps address significant unmet needs in cancer and autoimmune diseases by utilizing proprietary technology and strong collaborations with major pharmaceutical companies, enhancing its research and development efforts.

Five Things You Need to Know

Immutep is a leader in developing LAG-3 based immunotherapies.

Its flagship product, eftilagimod alpha, is in advanced clinical trial stages.

The company holds strategic partnerships with leading pharmaceutical firms.

Immutep is led by experienced industry experts with a strong track record.

The company has a global strategy focused on expanding clinical and commercial footprints.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Marc Voigt, MBA

Website

www.immutep.com

Headquarters

Sydney, NSW 2000, AU

IMMP Financials

Key Financial Metrics (TTM)

Gross Margin

-522.59%

Operating Margin

-2052.18%

Net Income Margin

-1404.13%

Return on Equity

-69.20%

Return on Capital

-87.03%

Return on Assets

-57.01%

Earnings Yield

-95.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$56.99M

Shares Outstanding

147.37M

Volume

187.63K

Avg. Volume

677.63K

Financials (TTM)

Gross Profit

-A$116.34M

Operating Income

-A$216.99M

EBITDA

-A$130.12M

Operating Cash Flow

-A$107.58M

Capital Expenditure

-A$602.91K

Free Cash Flow

-A$108.19M

Cash & ST Invst.

A$99.13M

Total Debt

A$1.21M

Immutep Performance Analysis

Immutep annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-06-30	AUD 123,566	N/A
2023	2023-06-30	AUD 0	N/A
2024	2024-06-30	AUD 0	N/A
2025	2025-06-30	AUD 0	N/A

Immutep sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-06-30	-18.0%
Q2	2024-12-31	81.8%
Q4	2025-06-30	-39.8%
Q2	2025-12-31	217.8%

Immutep annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-06-30	AUD -0.27	N/A
2023	2023-06-30	AUD -0.30	11.0%
2024	2024-06-30	AUD -0.23	-21.8%
2025	2025-06-30	AUD -0.27	17.2%

Immutep sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-06-30	N/A
Q2	2024-12-31	13.0%
Q4	2025-06-30	-74.0%
Q2	2025-12-31	-13.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

A$6.03M

+185.5%

Gross Profit

-A$40.60M

-3741.1%

Gross Margin

-6.74%

N/A

Market Cap

$56.99M

N/A

Market Cap/Employee

$1.08M

N/A

Employees

N/A

Net Income

-A$44.86M

-111.3%

EBITDA

-A$44.90M

-102.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

A$99.13M

-4.4%

Total Debt

A$1.21M

-25.1%

Accounts Receivable

A$37.52M

+510.4%

Inventory

A$0.00

N/A

Long Term Debt

A$949.60K

-32.4%

Short Term Debt

A$519.75K

+147.4%

Return on Assets

-57.01%

N/A

Return on Invested Capital

-1.22%

N/A

Free Cash Flow

-A$28.21M

-57.8%

Operating Cash Flow

-A$28.12M

-61.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MREOMereo BioPharma Group plc

MREOMereo BioPharma Group plc$0.31+0.46%

PRQRProQR Therapeutics N.V.

PRQRProQR Therapeutics N.V.$1.73-1.70%

TRDAEntrada Therapeutics, Inc.

TRDAEntrada Therapeutics, Inc.$6.55+12.35%

EDITEditas Medicine, Inc.

EDITEditas Medicine, Inc.$2.60-0.76%

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$5.05-2.13%

CAPRCapricor Therapeutics, Inc.

CAPRCapricor Therapeutics, Inc.$6.57+0.00%

CABACabaletta Bio, Inc.

CABACabaletta Bio, Inc.$2.62-4.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$8.41-0.06%

TAT&T

TAT&T$23.94-0.03%

SMRNuScale Power

SMRNuScale Power$7.59-0.08%

ORCLOracle

ORCLOracle$117.74-0.02%

CMGChipotle Mexican Grill

CMGChipotle Mexican Grill$34.24+0.02%

CVNACarvana

CVNACarvana$66.32+0.00%

SGOViShares Trust - iShares 0-3 Month Treasury Bond ETF

SGOViShares Trust - iShares 0-3 Month Treasury Bond ETF$100.68+0.00%

Questions About IMMP

What is the current price of Immutep?

Immutep is trading at $0.38 per share.

What is the 52-week range for Immutep?

Over the past 52 weeks, Immutep has traded between $0.29 and $3.53.

How much debt does Immutep have?

As of the most recent reporting period, Immutep reported total debt of A$1.07M.

How much cash does Immutep have on hand?

Immutep reported A$44.18M in cash and cash equivalents in its most recent financial results.

What is Immutep’s dividend yield?

Immutep does not currently have a dividend yield.

Immutep(NASDAQ) IMMP

Immutep Financials at a Glance

IMMP News

Why Immutep Limited Stock Popped Today

IMMP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Immutep

Products and Services

What Makes Immutep Limited Special

Five Things You Need to Know

IMMP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Immutep Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMMP

What is the current price of Immutep?

What is the 52-week range for Immutep?

How much debt does Immutep have?

How much cash does Immutep have on hand?

What is Immutep’s dividend yield?

Premium Investing Services